Relmada Therapeutics, Inc. (RLMD) analyst actions
Rating and price-target actions on RLMD in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the RLMD overview →
1 measured RLMD analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease | Press release | -1.25% | -1.25% |
Keep exploring
More RLMD: earnings → · SEC filings → · RLMD overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EVOTEC AG S/ADR (EVTCY) | 265 | 0.00% | 17% |
| MiMedx Group, Inc (MDXG) | 265 | +0.14% | 57% |
| HUTCHMED (China) Limited - American Depositary Shares (HCM) | 263 | 0.00% | 47% |
| iBio, Inc. (IBIO) | 263 | -0.38% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.